Skip to main content

A History of Gastric or Duodenal Ulcers

0
Pipeline Programs
1
Companies
12
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Takeda
TakedaTOKYO, Japan
1 program
VonoprazanN/A5 trials
Active Trials
NCT04198363Completed510Est. Nov 2021
NCT03116841Completed3Est. Dec 2017
NCT03050307Completed234Est. May 2020
+2 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
TakedaVonoprazan
TakedaVonoprazan
TakedaVonoprazan
TakedaVonoprazan
TakedaVonoprazan
TakedaVonoprazan
TakedaVonoprazan
TakedaVonoprazan
TakedaVonoprazan
TakedaVonoprazan
TakedaVonoprazan
TakedaVonoprazan

Clinical Trials (12)

Total enrollment: 9,583 patients across 12 trials

Vonoprazan Study of Investigating the Effect on Sleep Disturbance Associated With Reflux Esophagitis- Exploratory Evaluation

Start: Aug 2017Est. completion: Dec 20173 patients
Phase 4Completed

A Study to Evaluate the Efficacy and Safety of Bismuth-Containing Quadruple Therapy With Oral Vonoprazan (TAK-438) 20 mg Compared to Esomeprazole 20 mg Twice Daily in Paticipants With Helicobacter Pylori Infection

Start: Apr 2020Est. completion: Nov 2021510 patients
Phase 3Completed

Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Gastric Ulcer Participants With or Without Helicobacter Pylori Infection

Start: Apr 2017Est. completion: May 2020234 patients
Phase 3Completed

Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Duodenal Ulcer Participants With or Without Helicobacter Pylori Infection

Start: Apr 2017Est. completion: Jul 2019533 patients
Phase 3Completed

Efficacy and Safety of Vonoprazan Compared to Lansoprazole in the Maintenance Treatment of Erosive Esophagitis

Start: Apr 2015Est. completion: Dec 2018703 patients
Phase 3Completed

Efficacy and Safety of Oral Once-Daily Vonoprazan (TAK-438) in Participants With Erosive Esophagitis

Start: Mar 2015Est. completion: Jul 2017481 patients
Phase 3Completed

Phase 3 Study to Evaluate the Acid-Inhibitory Effect of Multiple Oral Doses of Vonoprazan (TAK-438)

Start: Jan 2014Est. completion: Mar 201420 patients
Phase 3Completed

Comparison of Vonoprazan to Esomeprazole in Participants With Symptomatic GERD Who Responded Partially to a High Dose of Proton Pump Inhibitor (PPI)

Start: Jul 2016Est. completion: Oct 2018256 patients
Phase 2Completed

Special Drug Use Surveillance of Vonoprazan for "Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Low-dose Aspirin: Long-term Use"

Start: Sep 2016Est. completion: Feb 20191,119 patients
N/ACompleted

Special Drug Use Surveillance of Vonoprazan for "Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Non-steroidal Anti-inflammatory Drugs: Long-term Use"

Start: Sep 2016Est. completion: Apr 20201,304 patients
N/ACompleted

Special Drug Use Surveillance of Vonoprazan for "Maintenance Therapy of Reflux Esophagitis: Long-term Use"

Start: Mar 2016Est. completion: Aug 20181,237 patients
N/ACompleted

Drug Use Surveillance of Vonoprazan for "Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis"

Start: Mar 2016Est. completion: Oct 20183,183 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.